NORMAL SITUATION

dualyx

Company — Normal situation.

Financial year 2025 · Closed on 17/11/2025

Net result24,1 k €+100,7 %over 1 year
Gross margin25,5 k €+101,2 %over 1 year
Equity1,6 M €+1,5 %over 1 year
Workforce0,0 ETP-100,0 %over 1 year

Identity

Source · BCE/KBO

dualyx is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0737.938.386
Legal form
Public limited company
Contributed capital
5 226 445,33 €
Latest accounts
17/11/2025
Average workforce
0,0 ETP
Joint committees (2)
  • 207
  • 20700
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 6 filings

Trend over 6 financial years

20252024202320222021
Income statement
Gross margin25,5 k €-2,1 M €506,9 k €-2,1 M €-1,2 M €
EBITDA23,1 k €-3,5 M €-633 k €-2,6 M €-1,4 M €
Operating result23,1 k €-3,5 M €-5,3 M €-2,8 M €-1,6 M €
Net result24,1 k €-3,6 M €-5 M €-2,8 M €-1,6 M €
Balance sheet
Equity1,6 M €1,6 M €22,6 M €2,6 M €5,3 M €
Total assets1,6 M €1,8 M €24,3 M €3,8 M €6,6 M €
Cash1,4 M €1,6 M €11,6 M €2,3 M €4,6 M €
Debts4 k €175,5 k €1,6 M €615,5 k €251,8 k €
Other
Workforce0,0 ETP7,9 ETP9,6 ETP––

Board of directors

Source · NBB, accounts to 17/11/2025

7 active · 20 ended

Active mandates

Marco Boorsma

Director · since 29 février 2024 · until 17 novembre 2025

Active
Bernard Coulie

Director · since 31 mai 2023 · until 17 novembre 2025

Active
Aneta Maria Sottil

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Beach Biotech BV

Director · since 25 avril 2023 · until 17 novembre 2025 · 0801.072.421

Represented by Wouter Verhoeven

Active
Ena Sabina Prosser

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Katja Rosenkranz

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Participatiemaatschappij Vlaanderen

Director · since 25 avril 2023 · until 17 novembre 2025 · 0455.777.660

Represented by Tine Marie J. Bekaert

Active

Ended mandates

Marco Boorsma

Director · since 29 février 2024 · until 11 mai 2030

Ended
Bernard Coulie

Director · since 31 mai 2023 · until 11 mai 2029

Ended
Aneta Maria Sottil

Director · since 25 avril 2023 · until 11 mai 2029

Ended
Beach Biotech BV

Director · since 25 avril 2023 · until 11 mai 2029 · 0801.072.421

Represented by Wouter VERHOEVEN

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202121/11/2019
Closing of the financial year17/11/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year11 months12 months12 months12 months12 months14 months
Filing date03/04/202626/06/202527/05/202401/06/202310/06/202211/06/2021
General meeting17/11/202520/06/202513/05/202411/05/202311/05/202211/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 6 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model17/11/202517/11/202503/04/2026DutchPDF
Abridged model31/12/202420/06/202526/06/2025DutchPDF
Abridged model31/12/202313/05/202427/05/2024DutchPDF
Micro model31/12/202211/05/202301/06/2023DutchPDF
Micro model31/12/202111/05/202210/06/2022DutchPDF
Micro model31/12/202011/05/202111/06/2021DutchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 17/11/2025

7 active · 20 ended

Active mandates

Marco Boorsma

Director · since 29 février 2024 · until 17 novembre 2025

Active
Bernard Coulie

Director · since 31 mai 2023 · until 17 novembre 2025

Active
Aneta Maria Sottil

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Beach Biotech BV

Director · since 25 avril 2023 · until 17 novembre 2025 · 0801.072.421

Represented by Wouter Verhoeven

Active
Ena Sabina Prosser

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Katja Rosenkranz

Director · since 25 avril 2023 · until 17 novembre 2025

Active
Participatiemaatschappij Vlaanderen

Director · since 25 avril 2023 · until 17 novembre 2025 · 0455.777.660

Represented by Tine Marie J. Bekaert

Active

Ended mandates

Marco Boorsma

Director · since 29 février 2024 · until 11 mai 2030

Ended
Bernard Coulie

Director · since 31 mai 2023 · until 11 mai 2029

Ended
Aneta Maria Sottil

Director · since 25 avril 2023 · until 11 mai 2029

Ended
Beach Biotech BV

Director · since 25 avril 2023 · until 11 mai 2029 · 0801.072.421

Represented by Wouter VERHOEVEN

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Dissolution12/12/2025
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
    PDF
  • Mandates22/05/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares25/04/2024
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN
    PDF
  • Mandates23/02/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates24/07/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates10/05/2023
    KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates23/03/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares20/10/2021
    DIVERSEN - KAPITAAL - AANDELEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202524,1 k €↑
  2. 2025
    Name changeDualyx in vereffening
  3. 2024
    Annual accounts 2024-3,6 M €↑
  4. 2023
    Annual accounts 2023-5 M €↓
  5. 2022
    Annual accounts 2022-2,8 M €↓
  6. 2021
    Annual accounts 2021-1,6 M €↓
  7. 2021
    Name changeDualyx
  8. 2020
    Annual accounts 2020-1,1 M €